Dan Chevallard

Chief Financial Officer at Viracta Therapeutics, Inc.

Dan Chevallard

Dan Chevallard

Chief Financial Officer at Viracta Therapeutics, Inc.

Biography

Daniel R. Chevallard is former Chief Financial & Accounting Officer at Regulus Therapeutics, Inc. and former Controller & Senior Director-Finance at Prometheus Laboratories, Inc. He received an undergraduate degree from the University of San Diego.

Overview
Career Highlights

Viracta Therapeutics, Inc.
Regulus Therapeutics, Inc.

RelSci Relationships

115

Birthday

1979

Age

40

Contact Data
Trying to get in touch with Dan Chevallard? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Dan Chevallard likely has professional access to. A relationship does not necessarily indicate a personal connection.

President & Chief Executive Officer at Regulus Therapeutics, Inc.

Relationship likelihood: Strong

Secretary, Senior Vice President & General Counsel at Regulus Therapeutics, Inc.

Relationship likelihood: Strong

Professor at University of Washington

Relationship likelihood: Strong

Scientific Founder at Sapientia Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chief Financial Officer at Regulus Therapeutics, Inc.

Relationship likelihood: Average

Chief Executive Officer & President at Viracta Therapeutics, Inc.

Relationship likelihood: Average

Professional at Theragence, Inc.

Relationship likelihood: Average

Leader at Regulus Therapeutics, Inc.

Relationship likelihood: Average

Former Chief Research & Development Officer at Regulus Therapeutics, Inc.

Relationship likelihood: Average

Former Chief Medical Officer at Viracta Therapeutics, Inc.

Relationship likelihood: Average

Paths to Dan Chevallard
Potential Connections via
Relationship Science
You
Dan Chevallard
Chief Financial Officer at Viracta Therapeutics, Inc.
Education

The University of San Diego (USD) is a private Roman Catholic university in San Diego, California. The university offers 40 baccalaureate degrees, and several degrees in law, nursing, (masters, PhD, and DNP),and other doctorate programs. The university comprises seven different academic colleges.

Career History
Chief Financial & Accounting Officer
Prior - 2019

Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.

Controller & Senior Director-Finance
Prior

Prometheus Laboratories, Inc. develops and commercializes novel pharmaceutical and diagnostic products. Its enables physicians to provide individualized patient care. It applies the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and applies it to oncology. The firms markets and promotes pharmaceutical products and complementary proprietary diagnostic testing services. The company was founded by Jonathan Braun, Stephan R. Targan, Michael J. Walsh, and Scott L. Glenn in 1995 and is headquartered in San Diego, CA.

Chief Financial Officer
2019 - Current

Viracta Therapeutics, Inc. develops proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA.

Transactions
Details Hidden

Regulus Therapeutics, Inc. raised money in a private placement transaction

Public Holdings
Restricted data only for RelSci Professional users.
Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Dan Chevallard. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Dan Chevallard's profile does not indicate a business or promotional relationship of any kind between RelSci and Dan Chevallard.